User:I enjoy sandwiches/h

Source: Wikipedia, the free encyclopedia.
This page is about hormone replacement therapy in menopause. For other forms of hormone replacement therapy, see Hormone therapy.

Hormone replacement therapy (HRT), also known as menopausal hormone therapy (MHT) or postmenopausal hormone therapy (PHT, PMHT), is a form of

muscle mass, sexual dysfunction, and bone loss. They are in large part related to the diminished levels of sex hormones that occur during this time.[1][2]

The main

routes.[3]

The long-term effects of HRT on most organ systems vary by age and time since last physiologic exposure to hormones, and there can be large differences in individual regimens, factors which have made analyzing effect difficult.[7] There have been several large trials on hormone replacement in women, with the Women's Health Initiative (WHI) of the National Institutes of Health being the largest prospective study to date, and in particular having a significant impact since its inception. The WHI was a massive study of over 27,000 women conducted beginning in 1991 and taking place over 15 years, with multiple subsequent publications since that time analyzing its data.

The results of the WHI have been complex, and suggest both potential risks and benefits across different organ systems. Long term follow up of the WHI participants, however, has found no difference in

prospective studies to date.[9]

The current indications for use from the

vaginal atrophy, and prevention of osteoporosis.[10]

Indications

Women receiving this treatment are usually

peri-, or surgically menopausal. Menopause is the permanent cessation of menstruation resulting from loss of ovarian follicular activity, defined as beginning twelve months after the final natural menstrual cycle. This twelve month time point divides menopause into early and late transition periods known as 'perimenopause' and 'postmenopause'.[5] Premature menopause can occur if the ovaries are surgically removed, as can be done to treat ovarian or uterine cancer
.

Potential menopausal symptoms include:[1][2]

The most common of these are are

vaginal dryness.[5][13]

HRT may impact diseases like breast cancer, colorectal cancer, endometrial cancer, cardiovascular disease and dementia, though there is much debate in the medical community as to magnitude of effect and whether positive or negative.

HRT is often given as a short-term relief from menopausal symptoms during

perimenopause.[14]

Long term health effects

The effects of HRT on most organ systems vary by age and time since last physiologic exposure to hormones, and there can be large differences in individual regimens, factors which have made analyzing effect difficult.[7] Demographically, the vast majority of data available is in postmenopausal American women with concurrent pre-existing conditions, and with a mean age of over 60 years.[15]

The Women's Health Initiative (WHI) of the National Institutes of Health (NIH) is a massive study of over 27,000 women beginning in 1991 and has been the largest prospective analysis of HRT effects in menopause to date. Successive analyses have found sometimes contradictory results, with the most recent publication in 2017 finding no difference for all cause mortality with HRT.[7]

Potential benefits

Bone density

bone mineral density. It also helps collagen formation, which in turn improves texture of the intervertebral discs and bone matrix.[18]

Cardiovascular disease

coronary heart disease with HRT vary by age and years since onset of menopause. Women aged 50 to 59 using HRT have a lower risk of coronary heart disease,[19] as do women who are within five years of the onset of menopause.[20] There may be an increase in heart disease in older patients taking HRT, though this is only statistically significant in individuals twenty years post menopause.[16] There is no actual difference in long-term mortality from HRT, regardless of age.[7]

A

venous thromboembolism into account, the reviewers came to the conclusion that HRT had little benefit in cardiovascular disease.[21]

HRT also improves

ABC transporters.[22]

Endometrial cancer

Endometrial cancer can be associated with HRT, particularly in those not taking a progestogen.

In postmenopausal women, continuous combined estrogen plus progestin decreases endometrial cancer incidence.[23] The duration of progestogen therapy should be at least 14 days per cycle to prevent endometrial disease.[24]

Endometrial cancer has been grouped into two forms in the context of hormone replacement. Type 1 is the most common, can be associated with estrogen therapy, and is usually low grade. Type 2 is not related to estrogen stimulation and usually higher grade and poorer prognosis.[25] The endometrial hyperplasia that leads to endometrial cancer with estrogen therapy can be prevented by concomitant administration of progestogen.[25] The extensive use of high-dose estrogens for birth control in the 1970s is thought to have resulted in a significant increase in the incidence of type 1 endometrial cancer.[26]

Paradoxically, progestogens do promote the growth of

pelvic ultrasound can be performed before beginning HRT to make sure there are no underlying uterine or endometrial lesions.[25]

Muscle mass

Hormone replacement therapy in the form of estrogen and androgen can be effective at reversing the effects of aging on muscle.[27]

Neurodegenerative disorders

HRT may increase risk of dementia if initiated after 65 years of age, but have a neutral outcome or be neuroprotective for those between 50-55 years.[16] HRT can also improve executive and attention processes outside of the context of dementia in postmenopausal women.[28]

Sexual function

See also: Testosterone (medication) § Women

It is commonly misunderstood that as women complete their reproductive years, sexual activity stops altogether. Epidemiological surveys suggest that this is not true for most, with a recent study amongst women aged 40–69 revealing that 75% of women remain sexually active.[5] With increasing life spans, women today are living one third or more of their lives in a postmenopausal state, a period during which healthy sexuality can be integral to their quality of life.[29]

A major complaint among postmenopausal women is decreased libido and sexual function, and many may seek medical consultation.

inhibin (A and B) also occurs. Testosterone, a hormone more commonly associated with males, is also present in women at a lower level. It peaks at age 30, but declines gradually with age, so there is little variation across the lifetime and during the menopausal transition.[5] With surgical menopause, testosterone declines more sharply and can result in more severe symptoms.[5] HRT can help with sexual difficulties related to pain and lubrication.[6]

orgasm have also been noted.[13]

The effectiveness of hormone replacement can decline in some women after long-term use.[13] A number of studies have also found that the combined effects of estrogen/androgen replacement therapy can increase libido and arousal over estrogen alone.[13] Findings on a relatively new form of HRT called tibolone, a synthetic steroid with estrogenic, androgenic, and progestogenic properties, suggest that it has the ability to improve mood, libido, and physical symptoms of surgically menopausal women to a greater degree than ERT. In various placebo-controlled studies, improvements in vasomotor symptoms, emotional response, sleep disturbances, physical symptoms, and sexual desire have been observed.[6] Tibolone has been used in Europe for almost two decades but is not available North America at this point.[6]

Skin

Estrogen replacement promotes

fingernails.[18] There is no association of HRT, either positive of negative, with skin cancer.[31]

Potential risks

Breast cancer

There is a

randomized controlled trials to date.[32] The relative risk of breast cancer also varies depending on the interval between menopause and HRT and route of administration.[33]

Breast cancer may have an increased incidence with certain forms of HRT.

The WHI also found a non-significant trend in the estrogen-alone clinical trial towards a reduced risk of breast cancer, though estrogen is usually only given alone in the setting of a hysterectomy due to the effect of unopposed estrogen on the uterus.[19][34]

HRT has been more strongly associated with risk of breast cancer in women with a lower range body mass indices (BMIs). No breast cancer association has been found with BMIs of over 25.[35] It has been suggested by some that the absence of significant effect in some of these studies could be due to selective prescription to overweight women who have higher baseline estrone, or to the very low progesterone serum levels after oral administration leading to a high tumor inactivation rate.[36]

For women who previously have had breast cancer, it is recommended to first consider other options for menopausal effects, such as

cholesterol-lowering agents and aspirin for cardiovascular disease, and vaginal estrogen for local symptoms. Observational studies of systemic HRT after breast cancer are generally reassuring. If HRT is necessary after breast cancer, estrogen-only therapy or estrogen therapy with a progestogen may be safer options than combined systemic therapy.[37]

Colorectal cancer

In the WHI study, results were mixed. Women who took combined estrogen-progesterone therapy had a lower risk of getting

lymph nodes or distant sites than colorectal cancer in women not taking hormones.[31]

Ovarian cancer

A 2015 meta-analysis found that HRT was associated with an increased risk of

clear cell, endometrioid, or mucinous ovarian cancer.[39]

Pulmonary embolism and venous clotting

Clot in the greater saphenous vein; oral estrogen is associated with increased risk of venous clot due to increased liver formation of Vitamin K dependent clotting factors.

Comparisons between routes of administration suggest that when estrogens are taken orally the risk of a

clotting factors.[41] Taking progesterone at the same time can decrease this risk.[40]

Stroke

Multiple studies suggest that the possibility of HRT related stroke is absent if therapy is started within five years of menopause,

ischemic stroke.[42] Another large cohort of Danish women suggested that the specific route of administration was important, finding that although oral estrogen increased risk of stroke, transdermal application had no impact, and vaginal estrogen actually had a decreased risk.[8]

Available forms

See also: Sex-hormonal agent and List of sex-hormonal medications available in the United States

There are five major human steroid hormones: estrogens, progestogens,

glucocorticoids. Estrogens and progestogens are the two most often used in menopause. They are available in a wide variety of FDA approved and non–FDA-approved formulations.[9]

In women with intact uteruses, estrogens are almost always given in combination with progestogens, as long-term unopposed estrogen therapy is associated with a markedly increased risk of endometrial hyperplasia and endometrial cancer.[3] Conversely, in women who have undergone a hysterectomy or do not have a uterus, a progestogen is not required, and estrogen can be used alone. There are many combined formulations which include both estrogen and progestogen.

Specific types of hormone replacement include:[3]

Tibolone is a synthetic derivative of Mexican yam whose metabolites have estrogenic, progestogenic, and androgenic effects.[3]

Vaginal estrogen can improve local atrophy and dryness, with fewer systemic effects than estrogens delivered by other routes.[45] Sometimes an androgen, generally testosterone, is added to treat diminished libido. It may also treat reduced energy and help reduce osteoporosis after menopause.

Continuous versus cyclic

Dosage is often varied cyclically to more closely mimic the ovarian hormone cycle, with estrogens taken daily and progestogens taken for about two weeks every month or every other month, a schedule referred to as 'cyclic' or 'sequentially combined'. Alternatively, 'continuous combined' HRT can be given with a constant daily hormonal dosage.

Estrogen dosages for menopausal hormone therapy
Route/form Estrogen Low Standard High
Oral Estradiol 0.5–1 mg/day 1–2 mg/day 2–4 mg/day
Estradiol valerate 0.5–1 mg/day 1–2 mg/day 2–4 mg/day
Estradiol acetate 0.45–0.9 mg/day 0.9–1.8 mg/day 1.8–3.6 mg/day
Conjugated estrogens 0.3–0.45 mg/day 0.625 mg/day 0.9–1.25 mg/day
Esterified estrogens 0.3–0.45 mg/day 0.625 mg/day 0.9–1.25 mg/day
Estropipate 0.75 mg/day 1.5 mg/day 3 mg/day
Estriol 1–2 mg/day 2–4 mg/day 4–8 mg/day
Ethinylestradiola 2.5–10 μg/day 5–20 μg/day –
Nasal spray Estradiol 150 μg/day 300 μg/day 600 μg/day
Transdermal patch Estradiol 25 μg/dayb 50 μg/dayb 100 μg/dayb
Transdermal gel
 Estradiol 0.5 mg/day 1–1.5 mg/day 2–3 mg/day
Vaginal
 Estradiol 25 μg/day – –
Estriol 30 μg/day 0.5 mg 2x/week 0.5 mg/day
SC injection
 Estradiol valerate – – 4 mg 1x/4 weeks
Estradiol cypionate 1 mg 1x/3–4 weeks 3 mg 1x/3–4 weeks 5 mg 1x/3–4 weeks
Estradiol benzoate 0.5 mg 1x/week 1 mg 1x/week 1.5 mg 1x/week
SC implant Estradiol 25 mg 1x/6 months 50 mg 1x/6 months 100 mg 1x/6 months
Footnotes: a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: See template.

Route of administration

routes of administration:[3]

More recently developed forms of drug delivery are alleged to have increased local effect lower dosing, fewer side effects, and constant rather than cyclical serum hormone levels.

first pass metabolism through the liver. This in turn prevents an increase in clotting factors and accumulation of anti-estrogenic metabolites, resulting in fewer adverse side effects, particularly with regard to cardiovascular disease and stroke.[47]

Bioidentical hormone therapy

Main article:
Bioidentical hormone therapy

naturally occurring counterparts.[48][49] There are, however, FDA approved products containing hormones classified as 'bioidentical'.[9]

Bioidentical hormones can be used in either pharmaceutical or compounded preparations, with the latter generally not recommended by regulatory bodies due to their lack of standardization and regulatory oversight.[48] Most classifications of bioidentical hormones do not take into account manufacturing, source, or delivery method of the products, and so describe both non-FDA approved compounded products and FDA approved pharmaceuticals as 'bioidentical'.[9]

Bioidentical hormones in pharmaceuticals may have health benefits over their animal derived counterparts, including a potentially decreased risk of

venous thromboembolism, cardiovascular disease, and breast cancer.[48] As of 2012, guidelines from the North American Menopause Society, the Endocrine Society, the International Menopause Society, and the European Menopause and Andropause Society endorsed the reduced risk of bioidentical pharmaceuticals for those with increased clotting risk.[48][50]

Compounding

Compounding for HRT is generally discouraged by the FDA and medical industry in the United States due to a lack of regulation and standardized dosing.

U. S. Congress did grant the FDA explicit but limited oversight of compounded drugs in a 1997 amendment to the Federal Food, Drug, and Cosmetic Act (FDCA), but they have encountered obstacles in this role since that time. After 64 patient deaths and 750 harmed patients from a 2012 meningitis outbreak due to contaminated steroid injections, Congress passed the 2013 Drug Quality and Security Act, authorizing creation by the FDA of a voluntary registration for facilities that manufactured compounded drugs, and reinforcing FDCA regulations for traditional compounding.[51]

In the United Kingdom, on the other hand, compounding is a regulated activity. The Medicines and Healthcare products Regulatory Agency regulates compounding performed under a Manufacturing Specials license and the General Pharmaceutical Council regulates compounding performed within a pharmacy. All testosterone prescribed in the United Kingdom is bioidentical, with its use supported by the National Health Service. There is also marketing authorisation for male testosterone products. National Institute for Health and Care Excellence guideline 1.4.8 states: "consider testosterone supplementation for menopausal women with low sexual desire if HRT alone is not effective". The footnote adds: "at the time of publication (November 2015), testosterone did not have a United Kingdom marketing authorisation for this indication in women. Bio-identical progesterone is used in IVF treatment and for pregnant women who are at risk of premature labour."

Side effects

Some common and uncommon side effects include:[52]

Common

  • Headache
  • stomach cramps or bloating
  • Diarrhea
  • Appetite and weight changes
  • Changes in sex drive or performance
  • Nervousness
  • Brown or black patches on the skin
  • Acne
  • Swelling of hands, feet, or lower legs due to
    fluid retention
  • Changes in
    menstrual flow
  • Breast tenderness, enlargement, or discharge
  • Sudden difficulty wearing
    contact lenses

Uncommon

  • Double vision
  • Severe abdominal pain
  • Yellowing of skin or eyes
  • Severe depression
  • Unusual bleeding
  • Loss of appetite
  • Skin rash
  • Lassitude
  • Fever
  • Dark-colored urine
  • Light colored stool
  • Chorea[53]

Contraindications

The following are absolute and relative contraindications to HRT:[54]

Absolute contraindications

Relative contraindications

Medical and regulatory body statements

Current indications for HRT from the FDA include short-term treatment of menopausal symptoms such as hot flashes and vaginal atrophy, and prevention of osteoporosis.[10]

The

American College of Obstetrics and Gynecology (ACOG) approves of HRT for symptomatic relief of menopausal symptoms,[55] and advocates its usage beyond the age of 65 in appropriate clinical scenarios.[56]

The

The Endocrine Society stated that when taken during perimenopause or the initial years of menopause, HRT carries significantly fewer risks than previously published, and reduces all cause mortality in most patient scenarios.[58]

The American Association of Clinical Endocrinologists (AACE) has also released multiple position statements approving of HRT in appropriate clinical scenarios.[59]

History and research

The extraction of CEEs from the urine of pregnant

Premarin, one of the earlier forms of estrogen to be introduced.[60][61] From that time until the mid-1970s, estrogen was administered without a supplemental progestogen. Beginning in 1975, studies began to show that without a progestogen, unopposed estrogen therapy with Premarin resulted in an 8-fold increased risk of endometrial cancer, eventually causing sales of Premarin to plummet.[60] It was recognized in the early 1980s that the addition of a progestogen to estrogen reduced this risk to the endometrium.[60] This led to the development of combined estrogen–progestogen therapy, most commonly with a combination of conjugated equine estrogen (Premarin) and medroxyprogesterone (Provera).[60]

Women's Health Initiative and other trials

The WHI results were both positive and negative, suggesting that during the time of hormone therapy itself, there are increases in invasive

diabetes, and improvement of vasomotor symptoms. There also is an increased risk of dementia with HRT in women over 65, though when given earlier it appears to be neuroprotective. After the cessation of HRT, the WHI continued observe its participants, and found that most of these risks and benefits dissipated, though some elevation in breast cancer risk did persist.[16] Other studies have also suggested an increased risk of ovarian cancer.[39]

The actual trials were intended to be conducted between 1991 and 2006.

double-blind, placebo-controlled clinical trials of HRT in healthy women. One portion of the parallel studies followed over 16,000 women for an average of 5.2 years, half of whom took placebo, while the other half took a combination of CEEs and MPA (Prempro). This WHI estrogen-plus-progestin trial was stopped prematurely in 2002 because preliminary results suggested risks of combined CEEs and progestins exceeded their benefits. The first report on the halted WHI estrogen-plus-progestin study came out in July 2002.[62]

Initial data from the WHI in 2002 suggested mortality to be lower when HRT was begun earlier, between age 50 to 59, but higher when begun after age 60. In older patients, there was an apparent increased incidence of

United States Preventive Task Force (USPSTF) concluded that the harmful effects of combined estrogen and progestin therapy likely exceeded their chronic disease prevention benefits.[64][65]

In 2002 when the first WHI follow up study was published, with HRT in post menopausal women, both older and younger age groups had a slightly higher incidence of

heart attack and stroke were increased in older patients, although not in younger participants. Breast cancer was increased in women treated with estrogen and a progestin, but not with estrogen and progesterone or estrogen alone. Treatment with unopposed estrogen (i.e., an estrogen alone without a progestogen) is contraindicated if the uterus is still present, due to its proliferative effect on the endometrium. The WHI also found a reduced incidence of colorectal cancer when estrogen and a progestogen were used together, and most importantly, a reduced incidence of bone fractures. Ultimately, the study found disparate results for all cause mortality with HRT, finding it to be lower when HRT was begun during ages 50–59, but higher when begun after age 60. The authors of the study recommended that women with non-surgical menopause take the lowest feasible dose of hormones for the shortest time to minimize risk.[62]

The data published by the WHI suggested supplemental estrogen increased risk of venous thromboembolism and breast cancer but was protective against osteoporosis and colorectal cancer, while the impact on cardiovascular disease was mixed.[66] These results were later supported in trials from the United Kingdom, but not in more recent studies from France and China. Genetic polymorphism appears to be associated with inter-individual variability in metabolic response to HRT in postmenopausal women.[67][68]

Neither the WHI nor the MWS differentiated the results for different types of progestogens used. MPA – the type most commonly used in the United States – was the only one examined by the WHI, which in its analysis and conclusions extrapolated the benefits versus risks of MPA to all progestins. This conclusion has since been challenged by several researchers as unjustified and misleading, resulting in unreasonable, unnecessary avoidance by many women of HRT. In addition, subsequent findings released by the WHI showed that all cause mortality was not dramatically different between the groups receiving CEEs, those receiving estrogen and a progestogen, and those not on therapy.[69] In addition, the WHI trial was limited by low adherence, high attrition, inadequate power to detect risks for some outcomes, and evaluation of few regimens.[65] The double blinding limited validity of study results due to its effects on patient exclusion criteria. Patients who were experiencing symptoms of the menopausal transition were excluded from the study, meaning that younger women who had only recently experienced menopause were not significantly represented. As a result, while the average age of menopause is age 51, study participants were on average 62 years of age. Demographically, the vast majority were Caucasian, and tended to be slightly overweight and former smokers.

Results of the Women's Health Initiative (WHI) menopausal hormone therapy randomized controlled trials
Clinical outcome Hypothesized
effect on risk 		Estrogen and progestogen
(CEsTooltip conjugated estrogens 0.625 mg/day p.o. + MPATooltip medroxyprogesterone acetate 2.5 mg/day p.o.)
(n = 16,608, with uterus, 5.2–5.6 years follow up) 		Estrogen alone
(CEsTooltip Conjugated estrogens 0.625 mg/day p.o.)
(n = 10,739, no uterus, 6.8–7.1 years follow up)
HRTooltip Hazard ratio 95% CITooltip Confidence interval
AR
Tooltip Attributable risk 		HRTooltip Hazard ratio 95% CITooltip Confidence interval
AR
Tooltip Attributable risk
Coronary heart disease
 Decreased 1.24 1.00–1.54 +6 / 10,000 PYs 0.95 0.79–1.15 −3 / 10,000 PYs
Stroke Decreased 1.31 1.02–1.68 +8 / 10,000 PYs 1.37 1.09–1.73 +12 / 10,000 PYs
Pulmonary embolism Increased 2.13 1.45–3.11 +10 / 10,000 PYs 1.37 0.90–2.07 +4 / 10,000 PYs
Venous thromboembolism
 Increased 2.06 1.57–2.70 +18 / 10,000 PYs 1.32 0.99–1.75 +8 / 10,000 PYs
Breast cancer Increased 1.24 1.02–1.50 +8 / 10,000 PYs 0.80 0.62–1.04 −6 / 10,000 PYs
Colorectal cancer Decreased 0.56 0.38–0.81 −7 / 10,000 PYs 1.08 0.75–1.55 +1 / 10,000 PYs
Endometrial cancer – 0.81 0.48–1.36 −1 / 10,000 PYs – – –
Hip fractures Decreased 0.67 0.47–0.96 −5 / 10,000 PYs 0.65 0.45–0.94 −7 / 10,000 PYs
Total fractures Decreased 0.76 0.69–0.83 −47 / 10,000 PYs 0.71 0.64–0.80 −53 / 10,000 PYs
Total mortality Decreased 0.98 0.82–1.18 −1 / 10,000 PYs 1.04 0.91–1.12 +3 / 10,000 PYs
Global index – 1.15 1.03–1.28 +19 / 10,000 PYs 1.01 1.09–1.12 +2 / 10,000 PYs
Diabetes – 0.79 0.67–0.93 0.88 0.77–1.01
Gallbladder disease Increased 1.59 1.28–1.97 1.67 1.35–2.06
Stress incontinence – 1.87 1.61–2.18 2.15 1.77–2.82
Urge incontinence
 – 1.15 0.99–1.34 1.32 1.10–1.58
Peripheral artery disease – 0.89 0.63–1.25 1.32 0.99–1.77
Probable dementia Decreased 2.05 1.21–3.48 1.49 0.83–2.66
Abbreviations: CEs =
coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer (estrogen plus progestogen group only), hip fractures, and death
from other causes. Sources: See template.

The WHI reported

coronary heart disease, strokes and pulmonary emboli. The study also found statistically significant decreases in rates of hip fracture and colorectal cancer. "A year after the study was stopped in 2002, an article was published indicating that estrogen plus progestin also increases the risks of dementia."[70]
The conclusion of the study was that the HRT combination presented risks that outweighed its measured benefits. The results were almost universally reported as risks and problems associated with HRT in general, rather than with Prempro, the specific proprietary combination of CEEs and MPA studied.

After the increased clotting found in the first WHI results was reported in 2002, the number of Prempro prescriptions filled reduced by almost half. Following the WHI results, a large percentage of HRT users opted out of them, which was quickly followed by a sharp drop in breast cancer rates. The decrease in breast cancer rates has continued in subsequent years.[71] An unknown number of women started taking alternatives to Prempro, such as compounded bioidentical hormones, though researchers have asserted that compounded hormones are not significantly different from conventional hormone therapy.[72]

The other portion of the parallel studies featured women who were post hysterectomy and so received either placebo progestogen or CEEs alone. This group did not show the risks demonstrated in the combination hormone study, and the estrogen-only study was not halted in 2002. However, in February 2004 it, too, was halted. While there was a 23% decreased incidence of breast cancer in the estrogen-only study participants, risks of stroke and pulmonary embolism were increased slightly, predominantly in patients who began HRT over the age of 60.[73]

Several other large studies and meta-analyses have reported reduced mortality for HRT in women younger than age 60 or within 10 years of menopause, and a debatable or absent effect on mortality in women over 60.[74][75][76][77][58][78]

Though research thus far has been substantial, further investigation is needed to fully understand differences in effect for different types of HRT and lengths of time since menopause.[79][80][18]

Society and public perception

Wyeth controversy

See also: Medical ghostwriter

ghostwritten reviews and commentaries that were published in medical journals in order to promote unproven benefits of its HRT products, downplay their harms and risks, and cast competing therapies in a negative light.[81][82][83] Starting in the mid-1990s and continuing for over a decade, Wyeth pursued an aggressive "publication plan" strategy to promote its HRT products through the use of ghostwritten publications.[83] It worked mainly with DesignWrite, a medical writing firm.[83] Between 1998 and 2005, Wyeth had 26 papers promoting its HRT products published in scientific journals.[81]

These favorable publications emphasized the benefits and downplayed the risks of its HRT products, especially the "misconception" of the association of its products with breast cancer.

vision problems, and wrinkles.[82] In addition, Wyeth emphasized negative messages against the SERM raloxifene for osteoporosis, instructed writers to stress the fact that "alternative therapies have increased in usage since the WHI even though there is little evidence that they are effective or safe...", called into question the quality and therapeutic equivalence of approved generic CEE products, and made efforts to spread the notion that the unique risks of CEEs and MPA were a class effect of all forms of menopausal HRT: "Overall, these data indicate that the benefit/risk analysis that was reported in the Women's Health Initiative can be generalized to all postmenopausal hormone replacement therapy products."[82]

Following the publication of the WHI data in 2002, the stock prices for the pharmaceutical industry plummeted, and huge numbers of women stopped using HRT.[84] The stocks of Wyeth, which supplied the Premarin and Prempro that were used in the WHI trials, decreased by more than 50%, and never fully recovered.[84] Some of their articles in response promoted themes such as the following: "the WHI was flawed; the WHI was a controversial trial; the population studied in the WHI was inappropriate or was not representative of the general population of menopausal women; results of clinical trials should not guide treatment for individuals; observational studies are as good as or better than randomized clinical trials; animal studies can guide clinical decision-making; the risks associated with hormone therapy have been exaggerated; the benefits of hormone therapy have been or will be proven, and the recent studies are an aberration."[60] Similar findings were observed in a 2010 analysis of 114 editorials, reviews, guidelines, and letters by five industry-paid authors.[60] These publications promoted positive themes and challenged and criticized unfavorable trials such as the WHI and MWS.[60] In 2009, Wyeth was acquired by Pfizer in a deal valued at US$68 billion.[85][86] Pfizer, a company that produces Provera and Depo-Provera (MPA) and has also engaged in medical ghostwriting, continues to market Premarin and Prempro, which remain best-selling medications.[60][83]

According to Fugh-Berman (2010), "Today, despite definitive scientific data to the contrary, many gynecologists still believe that the benefits of [HRT] outweigh the risks in asymptomatic women. This non-evidence–based perception may be the result of decades of carefully orchestrated corporate influence on medical literature."[82] As many as 50% of physicians have expressed skepticism about large trials like the WHI and HERS.[87] The positive perceptions of many physicians of HRT in spite of large trials showing risks that potentially outweigh any benefits may be due to the efforts of pharmaceutical companies like Wyeth.[83][60]

Popularity

The 1990s showed a dramatic decline in prescription rates, though more recently they have begun to rise again.[88][89]

See also

References

  1. ^
    S2CID 29118146
    .
  2. ^
    PMID 20566620
    .
  3. ^
    S2CID 24616324
    .
  4. PMID 19733988
    .
  5. ^
    doi:10.2217/whe.09.24
  6. ^
    doi:10.1016/j.maturitas.2006.04.014
  7. ^
    S2CID 3427944
    .
  8. ^
    S2CID 207579406
    .
  9. ^
    PMID 21531972
    .
  10. ^ a b "USPTF Consensus Statement". 2012.
  11. S2CID 20392538
    .
  12. PMID 22533363
    .
  13. ^ a b c d e f g Sarrel, P.M. (2000). Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. Journal of Women’s Health and Gender-Based Medicine, 9, 25-32
  14. ^ "Menopause treatments". NHS. Retrieved 2018-02-23.
  15. PMID 28093732
    .
  16. ^
    PMID 24084921
    .
  17. S2CID 26110755
    .
  18. ^
    S2CID 33414205
    .
  19. ^
    S2CID 38249709
    .
  20. PMID 12904517
    .
  21. PMID 25754617
    .
  22. S2CID 203464
    .
  23. PMID 26668177
    .
  24. S2CID 38526018
    .
  25. ^
    PMID 23303565
    .
  26. ISBN 1-55009-163-8
    .
  27. PMID 25610174
    .
  28. S2CID 22921797
    .
  29. S2CID 43031351
    .
  30. doi:10.1016/j.maturitas.2003.10.005
  31. ^ a b "Menopausal Hormone Therapy and Cancer Risk". www.cancer.org. Retrieved 4 March 2019.
  32. PMID 17333341
    .
  33. PMID 23062839
    .
  34. S2CID 3956784
    .
  35. ISSN 0027-8874
    .
  36. S2CID 20808536
    .
  37. ^ Management of the menopause after breast cancer Archived 2016-04-07 at archive.today, from The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. College Statement C-Gyn 15. 1st Endorsed: February 2003. Current: November 2011. Review: November 2014
  38. doi:10.1016/S0140-6736(14)61687-1
    .
  39. ^
    S2CID 32195397
    .
  40. ^
    S2CID 4229701
    .
  41. S2CID 205827003
    .
  42. ^
    PMID 29149179.{{cite journal}}: CS1 maint: unflagged free DOI (link
    )
  43. PMID 12730248
    .
  44. PMID 18488873.{{cite journal}}: CS1 maint: unflagged free DOI (link
    )
  45. ^ Estrogen (Vaginal Route) from Mayo Clinic / Thomson Healthcare Inc. Portions of this document last updated: Nov. 1, 2011
  46. S2CID 29446836
    .
  47. S2CID 205452835
    .
  48. ^
    PMID 21464264
    .
  49. ^
    FDA
    . 2008-01-09. Retrieved 2009-02-17.
  50. S2CID 30292136
    .
  51. S2CID 30612542
    .
  52. PMID 28346192
    .
  53. S2CID 11410333
    .
  54. S2CID 25426141
    .
  55. ^ Lewis, Ricki. "ACOG Revises Guidelines on Treating Menopause Symptoms". login.medscape.com. Medscape. Retrieved 4 March 2019.
  56. ^ "Hormone Therapy and Heart Disease - ACOG". www.acog.org. Committee on Gynecologic Practice. Retrieved 4 March 2019.
  57. ^ "Medscape". www.medscape.com.
  58. ^
    doi:10.1210/jc.2009-2509
    . Retrieved Jan 16, 2015.
  59. PMID 28703650
    . Retrieved 1 March 2019.
  60. ^
    ISSN 2329-3691
    .
  61. ISBN 978-92-832-1291-1
    .
  62. ^
    S2CID 20149703
    .
  63. PMID 19196674
    .
  64. PMID 23396275
    .
  65. ^
    S2CID 25829459
    .
  66. ISBN 0-7817-4996-4
    .
  67. PMID 21117950
    .
  68. PMID 25922653
    .
  69. S2CID 16529377
    .
  70. ^ Mazzucco AE, Santoro E, DeSoto M, Lee JH (December 2010). "Hormone Therapy and Menopause". National Research Center for Women and Families.
  71. ^ Gina Kolata (2007-04-19). "Sharp Drop in Rates of Breast Cancer Holds". New York Times.
  72. ^ Roni Caryn Rabin (2007-08-28). "For a Low-Dose Hormone, Take Your Pick". New York Times. Many women seeking natural remedies have turned to compounding pharmacies, which use bioidentical hormones that are chemically synthesized but with the same molecular structure as hormones produced by a woman's body.
  73. ^ John Gever (2011-04-05). "New WHI Estrogen Analysis Shows Lower Breast Ca Risk". MedPageToday.
  74. PMID 19854329
    .
  75. PMID 16815651
    .
  76. PMID 9718051
    .
  77. PMID 15209595
    .
  78. PMID 9187066
    .
  79. PMID 21252179
    .
  80. S2CID 37219662
    .
  81. ^ a b c d Singer, Natasha (4 August 2009). "Medical Papers by Ghostwriters Pushed Therapy". The New York Times. Retrieved 13 July 2018.
  82. ^
    PMID 20838656.{{cite journal}}: CS1 maint: unflagged free DOI (link
    )
  83. ^
    ISBN 978-1-4129-8309-9
    .
  84. ^
    S2CID 207650230
    .
  85. ^ https://www.nytimes.com/2009/01/26/business/26drug.html
  86. ^ https://www.cnbc.com/id/33384753
  87. PMID 21949743
    .
  88. S2CID 205452835
    .
  89. ^ "Hormone therapy for brain performance: No effect, whether started early or late". www.sciencedaily.com.

External links

Category:Endocrine procedures Category:Life sciences industry Category:Menopause

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:I_enjoy_sandwiches/h&oldid=1118583422"